XML 40 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events	3 Months Ended
	Mar. 31, 2013
Subsequent Events	(9) Subsequent Events In April 2013, the FDA notified the Company that it accepted the Company’s ANCHOR sNDA for review. The acceptance of the sNDA indicates that the application is sufficiently complete to permit a substantive review by the FDA. The application is subject to a standard review and has been assigned a PDUFA date of December 20, 2013. The PDUFA date is the target date for the FDA to complete its review of the sNDA. However, there can be no assurance that the FDA will complete its review of the sNDA by this date. In addition, in April 2013, the FDA approved the Company’s sNDAs covering Chemport and BASF as additional Vascepa API suppliers.

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration